Master GxP, Regulatory Affairs & Documentation for Biopharmaceuticals in 4 weeks through hands-on, project-based online training with DSTC.
Biopharmaceutical development operates in a tightly regulated environment where non-compliance can lead to delays, rejections, or product recalls. A strong foundation in GxP principles, regulatory pathways, and high-quality documentation is essential for scientists, QA/RA professionals, and clinical teams working on biologics, biosimilars, vaccines, cell and gene therapies, and advanced therapeutics. Every participant receives a verified e-Certificate and e-Marksheet from the Deep Science & Technology Consortium.
Biopharmaceutical development operates in a tightly regulated environment where non-compliance can lead to delays, rejections, or product recalls. A strong foundation in GxP principles, regulatory pathways, and high-quality documentation is essential for scientists, QA/RA professionals, and clinical teams working on biologics, biosimilars, vaccines, cell and gene therapies, and advanced therapeutics.
1. Translate biotechnology theory into practical, reproducible analysis.
2. Build a defensible project you can showcase to supervisors, reviewers, or employers.
β’ Master's and senior undergraduate students specializing in biotechnology
β’ R&D engineers and working professionals applying biotechnology in industry
β’ Academics and educators building research or teaching capacity in biotechnology
β’ A demonstrable biotechnology project for your research or industry portfolio.
β’ A verified e-Certificate of competency and e-Marksheet from the Deep Science & Technology Consortium.
β’ GLP, GCP and GMP and the distinct activities each governs
β’ ICH Q7 to Q12 and the quality system expectations behind them
β’ Regulator roles: CDSCO, FDA and EMA and where their requirements diverge
β’ Attributable, legible, contemporaneous, original and accurate, plus the additions
β’ Audit trails, 21 CFR Part 11 and computerised system validation
β’ Data integrity findings as a leading cause of warning letters
β’ Batch records, SOPs, protocols and reports and their approval routes
β’ Good documentation practice: corrections, signatures and contemporaneous entry
β’ If it is not written down it did not happen, applied literally
β’ Deviation handling, root cause analysis and CAPA that addresses the cause
β’ Change control and its assessment of regulatory impact
β’ Internal audit, inspection readiness and responding to observations
β’ CTD and eCTD structure and what populates each module
β’ IND, BLA and marketing authorisation routes for biologics
β’ Biosimilar comparability and the additional demands of cell and gene therapy
| Parameter | Requirement |
|---|---|
| Covered Tool / Platform | AutoDock |
| Covered Tool / Platform | PyRx |
| Covered Tool / Platform | ChemDraw |
| Covered Tool / Platform | Discovery Studio |
| Covered Tool / Platform | ADMET Predictor |
| Covered Tool / Platform | Python |
| Covered Tool / Platform | SPSS |
Based on 0 scholar submissions
No verified reviews published yet. Be the first to share your academic experience.
Your rating will help prospective scholars. Ratings below 3 stars are routed privately to the faculty mentor for immediate response.